mark,
it's a very simple question with a very complex answer.
Every medical trial has rigid protocols on the type of patient that can be a candidate.
CCE (now AVH) have launched four DIFFERENT trials to date.
All the previous ones failed to get sufficient number of candidates.
They will talk in timelines, no. of clinics and many other terms.
To keep it simple - find out the following:
Total number of candidates required
Number of candidates so far
This will give you real progress.
I find out these numbers many times previously with CCE.
After the trial is complete you will still need 3 months for submission and 3 months for FDA processing.
If it runs smoothly.
AVH have demonstrated real progress in other ways.
ie - the simple ability to define an endpoint and then get to it. (Most people and ASX small caps fail at this)
If AVH demonstrate any ability to make real progress on FDA approval - then you will see the SP fly before the approval comes.
good luck
- Forums
- ASX - By Stock
- AVH
- question relating to trials
AVH
avita medical inc.
Add to My Watchlist
2.74%
!
$1.69

question relating to trials, page-2
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.69 |
Change
0.045(2.74%) |
Mkt cap ! $117.5M |
Open | High | Low | Value | Volume |
$1.70 | $1.73 | $1.67 | $457.4K | 270.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 25952 | $1.68 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.71 | 5000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 20000 | 1.680 |
2 | 10693 | 1.675 |
2 | 13000 | 1.670 |
2 | 3483 | 1.650 |
1 | 12487 | 1.645 |
Price($) | Vol. | No. |
---|---|---|
1.705 | 5000 | 1 |
1.720 | 580 | 2 |
1.730 | 3000 | 1 |
1.740 | 660 | 1 |
1.745 | 1000 | 1 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
AVH (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online